N6-苄氧羰基-L-赖氨酰胺单盐酸盐 | 58117-53-6

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 天然氨基酸及其衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N6-苄氧羰基-L-赖氨酰胺单盐酸盐
• 英文名称: (N6-Cbz)-Lys-NH2 hydrochloride
• 英文别名: Nε-Cbz-L-lysine hydrochloride；H-Lys(Cbz)-NH2*HCl；N^ε-benzyloxycarbonyl-L-lysine amide; hydrochloride；N^ε-Benzyloxycarbonyl-L-lysin-amid; Hydrochlorid；benzyl N-[(5S)-5,6-diamino-6-oxohexyl]carbamate;hydron;chloride
• CAS: 58117-53-6
• 化学式: C₁₄H₂₁N₃O₃*ClH
• 分子量: 315.8
• InChiKey: QSRGTPRDCDSKAY-YDALLXLXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.32
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: H-Lys(z)-nh2 hcl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: H-Lys(z)-nh2 hcl
CAS number: 58117-53-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H21N3O3.ClH
Molecular weight: 315.8

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N6-苄氧羰基-L-赖氨酰胺单盐酸盐 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 、 水 为溶剂， 反应 2.08h， 生成 (2,3,4,5,6-d5)-Phe-(N6-Cbz)-Lys-NH2
  参考文献：
  名称：

  [EN] DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA
  [FR] TÉTRAPEPTIDES DEUTÉRÉS QUI CIBLENT LES MITOCHONDRIES

  摘要：

  揭示了SBT-20和elamipretide（MTP-131）的氘代物。这些化合物可用于治疗和预防缺血再灌注损伤（例如心脏缺血再灌注损伤）或心肌梗死。

  公开号：

  WO2019099481A1
• 作为产物：
  描述：

  N^ε-(benzyloxycarbonyl)-N^α-(tert-butoxycarbonyl)-L-lysinamide 在 盐酸 作用下， 以 乙醚 、 水 为溶剂， 以85%的产率得到N6-苄氧羰基-L-赖氨酰胺单盐酸盐
  参考文献：
  名称：

  [EN] DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA
  [FR] TÉTRAPEPTIDES DEUTÉRÉS QUI CIBLENT LES MITOCHONDRIES

  摘要：

  揭示了SBT-20和elamipretide（MTP-131）的氘代物。这些化合物可用于治疗和预防缺血再灌注损伤（例如心脏缺血再灌注损伤）或心肌梗死。

  公开号：

  WO2019099481A1

文献信息

• Protease-catalysed synthesis of peptides containing histidine and lysine
  作者：Karin Beck-Piotraschke、Hans-Dieter Jakubke

  DOI：10.1016/s0957-4166(98)00134-7

  日期：1998.5

  trypsin-catalysed syntheses of peptides starting from simple acyl donor esters containing histidine at the P1-position (nomenclature according to Schechter and Berger[1]) and lysine derivatives as amino components were examined on the basis of their kinetic parameters. Despite higher specificity constants (kcat/KM) of trypsin-catalysed ester hydrolysis, α-chymotrypsin-catalysed acyl transfer to Nε-unprotected

  在此基础上研究了动力学控制的α-胰凝乳蛋白酶和胰蛋白酶催化的肽的合成，这些肽从在P 1位含有组氨酸的简单酰基供体酯（根据Schechter和Berger [1]的命名法）和赖氨酸衍生物作为氨基成分开始他们的动力学参数。尽管更高的特异性常数（K猫/ K中号）胰蛋白酶催化的酯水解的，α胰凝乳蛋白酶催化的酰基转移到N ε -unprotected赖氨酸衍生物在酰基转移到N得到相比于胰蛋白酶催化的反应更高的肽的产率，而ε胰蛋白酶催化的β-保护的赖氨酸衍生物的收率较高。冷冻系统中α-胰蛋白酶催化的酰基转移反应证明了冷冻的增产作用。使用特定的酯离去基团，可以减少酶的量和反应时间。在冷冻系统中，pH≥9时，H–Lys–OH的ε-氨基充当酰基受体。
• Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
  申请人：Fushimi Nobuhiko

  公开号：US20050272669A1

  公开（公告）日：2005-12-08

  The present invention provides pyrazole derivatives represented by the general formula: wherein R 1 represents H, an optionally substituted C 1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C 1-6 alkyl group etc.; R 2 represents H, a halogen atom, OH, an optionally substituted C 1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C 1-6 alkylene group etc.; Z represents —R B , —COR C etc. in which R B represents an optionally substituted C 1-6 alkyl group etc.; and R C represents an optionally substituted C 1-6 alkyl group etc.; R 4 represents H, an optionally substituted C 1-6 alkyl group etc.; and R 3 , R 5 and R 6 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

  本发明提供了由通式表示的吡唑衍生物：其中，R1代表H、可选取代的C1-6烷基等；Q和T中的一个代表由通式表示的基团：或由通式表示的基团：另一个代表可选取代的C1-6烷基等；R2代表H、卤素原子、OH、可选取代的C1-6烷基等；X代表单键、O或S；Y代表可选取代的C1-6亚烷基等；Z代表-RB、-CORC等，其中RB代表可选取代的C1-6烷基等；RC代表可选取代的C1-6烷基等；R4代表H、可选取代的C1-6烷基等；R3、R5和R6代表H、卤素原子等，其药学上可接受的盐或前药，具有在人类SGLT1中出色的抑制活性，可用作预防或治疗与高血糖相关的疾病，如糖尿病、糖耐量受损、空腹血糖受损、糖尿病并发症或肥胖症，以及与血中半乳糖水平增加相关的疾病，如半乳糖血症的治疗剂，以及包含它们的制药组合物、制药用途和制备它们的中间体。
• Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
  申请人：Teranishi Hirotaka

  公开号：US20060166899A1

  公开（公告）日：2006-07-27

  The present invention provides pyrazole derivatives represented by the general formula: wherein R 1 represents H, an optionally substituted C 1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C 1-6 alkyl group etc.; R 2 represents H, a halogen atom, OH, an optionally substituted C 1-6 alkyl group etc.; X represents a single bond, O or S; Y represents a single bond, a C 1-6 alkylene group etc.; Z represents CO or SO 2 ; R 4 and R 5 represent H, an optionally substituted C 1-6 alkyl group etc.; and R 3 , R 6 and R 7 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

  本发明提供了由下式表示的吡唑衍生物： 其中，R1代表H、可选取代的C1-6烷基等；Q和T中的一个代表由下式表示的基团： 另一个代表可选取代的C1-6烷基等；R2代表H、卤素原子、OH、可选取代的C1-6烷基等；X代表单键、O或S；Y代表单键、C1-6烷基亚基等；Z代表CO或SO2；R4和R5代表H、可选取代的C1-6烷基等；R3、R6和R7代表H、卤素原子等，其药学上可接受的盐或前药，具有在人类SGLT1中出色的抑制活性，并且作为预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症的药物，以及包含它们的制药组合物、制药用途和制备它们的中间体。
• WO2020131282A5
  申请人：——

  公开号：WO2020131282A5

  公开（公告）日：2022-11-21
• PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1548024B1

  公开（公告）日：2012-06-06